Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fate Therapeutics, Inc. (FATE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fate Therapeutics is a clinical-stage biopharmaceutical company whose common stock trades on the Nasdaq Global Market, and its Exchange Act reports offer detailed information on financial condition, clinical programs, and corporate actions related to its iPSC-derived cellular immunotherapy pipeline.
Among the key documents available are current reports on Form 8-K, where Fate Therapeutics reports material events such as quarterly financial results, corporate restructuring decisions, clinical data updates, and executive appointments. For example, recent 8-K filings describe financial results for specific quarters, a restructuring that includes a workforce reduction to streamline operations and extend cash runway, and detailed summaries of new and updated FT819 clinical data presented at scientific meetings. Other 8-K filings outline changes in board composition and the appointment of a Chief Financial Officer, including associated compensation terms and inducement equity awards.
Investors can also use SEC filings to confirm the company’s trading status, as Fate Therapeutics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market under the symbol FATE. Filings disclose the company’s principal executive office location by city and state, the par value of its common stock, and the use of inducement equity plans under Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, each new Fate Therapeutics filing is captured from EDGAR and paired with AI-powered summaries that highlight the most important points, such as clinical milestones, restructuring charges, or changes in leadership. Users can quickly scan Form 8-K items, then drill down into the full text for deeper analysis, helping them understand how regulatory disclosures relate to the company’s iPSC-derived CAR T-cell and NK-cell development strategy.
Fate Therapeutics Inc ownership update: The Vanguard Group filed Amendment No. 6 to its Schedule 13G/A reporting that it beneficially owns 0 shares of Common Stock, representing 0% of the class as reported. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report ownership separately. The amendment is signed on 03/26/2026.
Fate Therapeutics presents an in-depth annual overview of its strategy to develop off-the-shelf, iPSC-derived cellular immunotherapies for autoimmune diseases and cancer. The company engineers clonal iPSC master lines to mass-produce uniform T-cell and NK-cell therapies designed for on-demand, broad patient access.
The pipeline centers on FT819, a CD19-targeted CAR T-cell for systemic lupus erythematosus and other B cell–mediated autoimmune diseases, which has received FDA RMAT designation and shown early signals of deep B‑cell depletion and clinical activity with a fludarabine‑free or conditioning‑free approach. Additional programs include FT825 for HER2-positive solid tumors, FT836 and FT839 next‑generation CAR T cells incorporating Sword & Shield and dual‑CAR designs, and FT522, a CAR NK cell using Alloimmune Defense Receptor technology to reduce reliance on intensive chemotherapy.
The report highlights a broad risk profile typical for early-stage biotechnology, including heavy funding needs, clinical and regulatory uncertainty, complex manufacturing, reliance on partners such as Ono Pharmaceutical, and extensive dependence on patents and licensed technologies to protect its iPSC platform and product candidates.
Fate Therapeutics, Inc. reported fourth-quarter and full-year 2025 results and highlighted progress in its off-the-shelf CAR T-cell pipeline. For 2025, collaboration revenue was $6.6 million, down from $13.6 million in 2024, reflecting lower partnered activity. Total operating expenses fell sharply to $154.4 million from $223.9 million, driven by lower research and development and general and administrative costs, including reduced stock-based compensation and the absence of prior-year impairment.
The company’s 2025 net loss narrowed to $136.3 million from $186.3 million, with basic and diluted net loss per share improving to $1.15 from $1.64. As of December 31, 2025, Fate held $205.1 million in cash, cash equivalents, and investments, and common shares outstanding were 115.4 million. Management projects an operating runway through year-end 2027, supported by this cash position and an expected 30% reduction in 2025 operating expenses versus 2024, which they believe will enable key clinical and collaboration milestones.
Operationally, the company advanced FT819, its off-the-shelf CD19 CAR T-cell program for autoimmune diseases, including outpatient treatment and enrollment across 16 sites, and reported early clinical activity for FT836 in colorectal cancer without conditioning chemotherapy, alongside preclinical progress for FT839.
Fate Therapeutics reported new equity awards to Chief Legal and Compliance Officer Cindy Tahl. On January 15, 2026, she was granted 100,000 shares of common stock at an acquisition price of $0.00, reported as an award of restricted stock units. These RSUs vest in four equal installments on January 8, 2027, 2028, 2029 and 2030, with each RSU converting into one share of common stock upon settlement. Following this grant, she beneficially owns 487,081 common shares directly.
She was also granted a stock option for 400,000 shares of common stock with an exercise price of $1.05 per share. This option vests in 36 equal monthly installments after January 1, 2026, becoming fully vested and exercisable on January 1, 2029, contingent on continued service with the company.
Fate Therapeutics Chief Financial Officer Adawi Kamal reported new equity awards, including restricted stock units and stock options. On January 15, 2026, Kamal received 25,000 restricted stock units that vest in four equal installments on January 8 of each year from 2027 through 2030, subject to continued service. Each unit represents the right to receive one share of common stock upon settlement.
Kamal was also granted stock options for 75,000 shares of common stock at an exercise price of $1.05 per share. These options vest in 36 equal monthly installments following January 1, 2026, becoming fully vested and exercisable on January 1, 2029, if service continues. After these grants, Kamal beneficially owned 100,000 shares of common stock directly and held 75,000 stock options.
Fate Therapeutics reported that its President and CEO, Bahram Valamehr, received new equity awards. On January 15, 2026, he was granted 335,000 shares of common stock at a price of $0.00, representing restricted stock units that vest in four equal parts on January 8 of 2027, 2028, 2029 and 2030, contingent on continued service. On the same date, he was also granted a stock option for 1,300,000 shares of common stock at an exercise price of $1.05 per share, vesting in 36 equal monthly installments after January 1, 2026, and becoming fully vested on January 1, 2029, subject to continued service. Following the stock award, he beneficially owned 664,708 shares of common stock directly, and held 1,300,000 stock options directly.
Fate Therapeutics Chief Legal and Compliance Officer Cindy Tahl reported an automatic sale of company stock tied to restricted stock unit (RSU) vesting. On January 9, 2026, she sold 10,589 shares of common stock at a weighted average price of $1.0648 per share, with individual sale prices ranging from $1.05 to $1.09. The filing explains these were the required number of shares sold to cover tax withholding obligations arising from the vesting of 17,500 RSU-based shares granted on January 15, 2025 and 8,326 RSU-based shares granted on January 25, 2022. The transactions were executed under a pre-arranged “sell-to-cover” election and were not made at her discretion. After the sales, Tahl beneficially owned 387,081 shares of Fate Therapeutics common stock directly.
Fate Therapeutics President and CEO Bahram Valamehr reported the sale of 5,190 shares of the company’s common stock on January 9, 2026 at a weighted average price of $1.0708 per share. After this transaction, he beneficially owned 329,708 shares.
According to the filing, the shares were sold only in an amount required to cover tax withholding obligations arising from the vesting of 8,326 shares underlying previously granted RSUs. The sales were automatically executed under an irrevocable sell-to-cover election and were not made at his discretion.
Fate Therapeutics has a Form 144 notice indicating a shareholder plans to sell 10,589 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 11,275.17. These shares were acquired on 01/08/2026 via restricted stock vesting as compensation from the issuer. Shares of common stock outstanding were 115,352,289 at the time referenced, which serves as a baseline figure.
A shareholder has filed a notice of intent to sell 5,190 shares of common stock through Fidelity Brokerage Services LLC on or about 01/09/2026, with trading on the NASDAQ exchange. The shares have an aggregate market value of $5,557.45 based on the information provided and are part of a total of 115,352,289 shares outstanding. These securities were acquired from the issuer on 01/08/2026 through restricted stock vesting as compensation, with the same date shown for acquisition and payment.